Treatment of non-ulcer dyspepsia: A meta-analysis of placebo-controlled prospective studies

Scandinavian Journal of Gastroenterology

Volumn 36, Issue 9, 2001, Pages 934-941

  Allescher, H D ^a   Bockenhoff A ^a   Knapp, G ^a   Wienbeck, M ^a   Hartung, J ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Gastroprokinetics; Meta analysis; Non ulcer dyspepsia

Indexed keywords

CIMETIDINE; CISAPRIDE; DOMPERIDONE; HISTAMINE H2 RECEPTOR ANTAGONIST; PLACEBO; PROKINETIC AGENT; RANITIDINE;

ADULT; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DYSPEPSIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 0034916957     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655201750305440     Document Type: Article

References (46)

1. Dyspepsia and dyspepsia subgroups: A population-based study
2. U.S. householder survey of functional gastrointestinal disorders - Prevalence, sociodemography, and health impact
3. American Gastroenterological Association medication position statement: Evaluation of dyspepsia
4. Emperical H2-blocker therapy or prompt endoscopy in management of dyspepsia
5. Cisapride versus metoclopramide in the treatment of functional dyspesia
6. Functional dyspepsia. Current treatment recommendations
7. Drug treatment of functional dyspepsia: A meta-analysis of randomized controlled trials
8. Meta-analysis of antisecretory and gastrokinetic compounds in functional dyspepsia
9. Clinical efficacy and safety of cisapride and clebopride in the management of chronic functional dyspepsia: A double blind, randomized study
10. Meta-analysis in clinical trials
11. Effect of the non-antidopaminergic drug cisapride on post-prandial nausea
12. Non-cholinergic, non-antidopaminergic treatment of chronic digestive symptoms suggestive of a motility disorder: A two step pilot evaluation of cisapride
13. Cisapride in the treatment of functional non-ulcer dyspepsia
14. Cisapride in the management of chronic functional dyspepsia: A multicenter, double blind, placebo-controlled study
15. Efficacy of cisapride in patients with non-ulcer dyspepsia. A placebo-controlled study
16. Cisapride in non-ulcer dyspepsia
17. Relief of epigastric pain in non-ulcer dyspepsia: Controlled trial of the promotility drug cisapride
18. Cisapride treatment of patients with non-ulcer dyspepsia and erosive prepyloric changes
19. Cisapride in chronic dyspepsia: Results of a double blind, placebo controlled trial
20. Efficacy of cisapride in functional dyspepsia resistant to domperidone or metoclopramide: A double blind, placebo-controlled study
21. A double-blind, randomized, placebo-controlled trial of cisapride in Saudi Arabs with functional dyspepsia
22. Efficacy of cisapride therapy in functional dyspepsia
23. Effect of cisapride on functional dyspepsia in patients with and without histological gastritis: A double-blind, plazebo-controlled trial
24. Chronic dyspepsia. Double blind treatment with domperidone (R33812) or a placebo
25. Domperidone in the treatment of functional dyspepsia in patients with delayed gastric emptying
26. Domperidone in chronic dyspepsia: A pilot open study and a multicentre general practice cross-over comparison with metoclopramide and placebo
27. Oral domperidone in chronic postprandial dyspepsia. A double blind placebo-controlled evaluation
28. Use of the peripheral domapine antagonist, domperidone, in the management of gastrointestinal symptoms in patients with irritable bowel syndrome
29. Symptomatic improvement by domperidone in patients with functional dyspepsia
30. Non-ulcer dyspepsia, duodenitis and cimetidine
31. Cimetidine in the management of symptomatic patients with duodenitis
32. Symptomatic treatment of non-ulcer dyspepsia with cimetidine
33. Controlled clinical trial of treatment with cimetidine for non-ulcer dyspepsia
34. Controlled trials in gastrodyspepsia: A methodological aspect
35. Treatment with cimetidine, antacids, or placebo in patients with dyspepsia of unknown origin
36. Cimetidine in the treatment of non-ulcer dyspepsia: Results of a randomised double blind placebo-controlled study
37. Dyspepsia: Incidence of non-ulcer disease in a controlled trial of ranitidine in general practice
38. Clinical investigation of ranitidine in patients with gastritis
39. Ranitidine in the treatment of non-ulcer dyspepsia: A placebo controlled study in the Federal Republic of Germany
40. A general parametric approach to the meta-analysis of randomized clinical trials
41. Problems induced by meta-analysis
42. The management of acid-related dyspepsia in general practice: A comparison of an omeprazole versus an antacid-alginate/ranitidine management strategy
43. Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice
44. Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia
45. Prospektive Epidemiologische Studie der Oberbauchbeschwerden (PRESTO). Grundlagen und erste ergebnisse